YFYa-Xing Fang

Ya-Xing Fang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ya-Xing Fang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Construction and Validation of a Model for Predicting Cervical Intraepithelial Neoplasia Grade II+: A Cross-Sectional Population Study via Machine Learning

    by Juan He, Kang-Jia Chen, Ya-Xing Fang, Yu-Feng He, Lan Xiang, Xue-Mei Wang, Ming-Li Zhou, Shu-Guang Zhou, Jing-Jing Hu

    Cervical cancer, as the leading malignant tumor among women globally, underscores the critical need for early screening; however, effective models for predicting cervical lesions remain lacking. To construct a predictive model for cervical intraepithelial neoplasia II+(CINII+), and to compare the predictive performance of machine learning models integrating thinprep cytologic test (TCT) + human papillomavirus (HPV) testing with clinical data versus TCT combined with traditional clinical data for CIN II+. Clinical data from women undergoing cervical cancer screening at Linquan Maternity and Child Healthcare Hospital (2020–2024) were collected, including TCT results, HPV status, cervical pathology, age, sexual history and other clinical data. Ten machine learning algorithms were applied to develop two predictive models: Model 1(TCT+HPV+clinical data) and Model 2(TCT+traditional clinical data). Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curves and decision curve analysis (DCA). Multivariate logistic regression analysis showed that HPV positivity, TCT indicates High-Grade Squamous Intraepithelial Lesion(HSIL), colposcopy result indicates a high-grade lesion and the first age of pregnancy as predictors of CINII+. Model 1 (TCT+HPV+clinical data) demonstrated significantly higher predictive efficacy than Model 2(TCT+clinical data), the difference in AUC is statistically significant. (P=0.006 in training set; P=0.035 in testing set). The TCT+HPV-integrated model outperformed the TCT-only model in predicting CIN II+, supporting the incorporation of HPV testing into routine screening to enhance early diagnostic accuracy.


  • Open Access

    Extracellular Trap-Related Genes as Potential Diagnostic Biomarkers for Endometriosis

    by Ya-Xing Fang, Yu-Feng He, Bing-Bing Wang, Juan He, Yang Dong, Guo Chen, Shu-Guang Zhou

    Background: Endometriosis (EM), a prevalent gynecological disorder in reproductive-age women, lacks reliable noninvasive diagnostic tools. EM may be detected by neutrophil extracellular traps (NETs), which are essential to inflammation and immunological regulation. This research utilized 13 machine learning algorithms to improve the predictive precision of the diagnostic model and pinpointed four potential biomarkers that could aid in the diagnosis of EM. Methods: Using the GSE141549 dataset, we combined differentially expressed genes with NETs-related markers to identify key genes linked to EM. We performed functional analysis to understand their biological roles. Through 13 machine learning methods, we built 107 different models and selected four central genes: CEACAM1, FOS, PLA2G2A, and THBS1. We developed a diagnostic model, evaluating its performance with ROC curves, calibration plots, and decision curve analysis; its robustness was rigorously assessed through 10-fold cross-validation. Results: The four-gene model demonstrated superior performance, with high accuracy in the training set (AUC: 0.962), robust generalizability in cross-validation (mean AUC: 0.975) and external cohorts, confirmed clinical utility, and consistent gene expression across multiple datasets. Conclusion: This study identifies CEACAM1, FOS, PLA2G2A, and THBS1 as promising biomarkers for endometriosis. Their association with immune infiltration may improve early detection strategies, highlighting the potential for developing non-invasive diagnostic tools for EM in the future.